Samyang’s‘Croquis’to be presented at IMCAS Asia Class 2020

- Introduce Croquis at IMCAS Asia Class 2020

- Dr. Choi’s (PIENA Clinic) session on various thread lifting techniques using Croquis

- Focus on evidence-based marketing, expected to present clinical case study results at AMWC 2020

 ▲ Samyang Biopharm will be participating at the 2020 IMCAS Asia Class to demonstrate thread lifting techniques with Croquis.

Samyang Biopharm is officially kicking off to promote its first medical aesthetic brand ‘Croquis’.

Samyang will be participating at the 2020 IMCAS(International Master course on Aging Science) Asia Class to demonstrate the excellence of Croquis PDO thread.

Marking its 14^th year, IMCAS Asia is one of the largest medical aesthetic congresses in the world, focused in Asia Pacific regions. In 2019, it was held in Indonesia with about 80 companies and more than 1,500 medical-related participants. IMCAS Asia 2020 will be held in Bangkok, Thailand from October 15^th to 17^th. IMCAS Asia Class 2020 will also be held on the 17^th, separately from the original congress as an online course.

Samyang Biopharm will illustrate the excellence of its medical aesthetic brand Croquis to medical-related professionals from all around the world. The term ‘Croquis’ refers to an artistic line drawing technique of describing an object or person in a short period of time. As such, Croquis aims to provide natural beauty to its patients.

This year, Dr. Ho Sung Choi from PIENA Clinic, Korea will be sharing his technique in achieving optimal and natural lifting effect with various types of PDO threads. This includes inserting the cannula and maximizing the level of tissue repositioning. Dr. Choi is an advisory board member of Sinclair Pharma(Silhouette Soft, Ellanse) and Merz Aesthetics(Radiesse, Belotero).

“We have established a common goal of gathering various data to achieve the best outcome for each indication”, said Dr. Choi and added that “I look forward to increasing the credibility of Croquis by gathering clinical data to provide natural and safe beauty to the patients”.

Samyang has been receiving positive feedback from its partners, especially with its focus on evidence-based marketing strategy despite its somewhat late entry into the market. While other brands focus on pre/post-operational effects, Samyang aims to prove the close relationship between biomechanical characteristics of threads and clinical efficacy.

“Samyang prepared this webinar in hope to promote Croquis despite the ongoing pandemic with Covid-19. By setting IMCAS Asia Class as a cornerstone, Samyang will share the excellence of Croquis and focus on online academic marketing”, said an official from Samyang.

Samyang is also expected to participate at the upcoming AMWC(Aesthetic and anti-aging Medicine World Congress) 2020 from November 5th to 7th. Samyang will be presenting the results from its clinical case study that had been ongoing since December 2019 in France. In order to reaffirm the rheological advantage and clinical efficacy of Croquis, Samyang is closely collaborating with doctors from Spain, France, and the US. By working together with global KOL(Key Opinion Leader)’s, Samyang plans to conduct evidence-based marketing strategy using the data from different regions.

Meanwhile, Samyang Biopharm is expecting the launch of its PCL biostimulator Lafullen, currently conducting clinical study with local patients. Samyang expects Lafullen to last up to 24 months, much longer than HA fillers and hopes to achieve a better and safer product.